Friday, January 13, 2006 1:13:58 AM
Drug Maker Agrees to Pay Partner Sanofi $1.3 Billion To Gain Control of Exubera
By SCOTT HENSLEY, Staff Reporter of THE WALL STREET JOURNAL, January 13, 2006
Pfizer Inc. has agreed to pay $1.3 billion to Sanofi-Aventis SA for the world-wide rights to Exubera, an inhaled form of insulin the companies had previously planned to develop and market together.
The pact hands Pfizer of New York control of a drug that could be a hit, following a dispute with its French partner.
The Food and Drug Administration is expected to decide within weeks whether Pfizer can begin selling Exubera. In September, a panel of advisers to the FDA recommended the agency approve the drug. Sales forecasts for Exubera, which would be the first form of insulin taken without piercing the skin, vary because its main virtue is convenience. Some analysts expect the drug to be a modest seller while others project it could reap a billion dollars annually within a few years.
The agreement, announced last night, settles the commercial status of the experimental drug in the wake of Sanofi Synthelabo SA's acquisition of Aventis SA in 2004, creating Sanofi-Aventis.
Pfizer had teamed with Aventis to develop Exubera, and asserted that the merger triggered a change-of-control clause in their contract that opened the door to renegotiation of the agreement. Sanofi disputed that interpretation. Pfizer pursued the matter in U.S. and German courts, leading to the new deal reached yesterday, a company spokesman said.
Besides world-wide development and marketing rights, Pfizer will gain control of the manufacturing facilities for Exubera in Frankfurt that it previously owned jointly with Sanofi. Pfizer expects the deal to close by the end of February.
The new arrangement doesn't affect Nektar Therapeutics, Pfizer's other partner in the development. Nektar, San Carlos, Calif., remains entitled to royalties based on net sales of Exubera. Nektar provided technology to produce powdered insulin that could be inhaled.
The FDA review of Exubera has been delayed for years over concerns that the drug could hurt breathing capacity with long-term use. Pfizer and its partners studied Exubera in more than 3,500 patients, some who took it for as long as seven years. The declines in lung function appeared to be small and were reversible when patients stopped using the drug, according to data presented by Pfizer to the FDA advisory panel in September. If Exubera is approved, Pfizer pledged to study it further.
http://online.wsj.com/article/SB113711425479245490.html?mod=yahoo_hs&ru=yahoo
Recent NKTR News
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 09/03/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:15:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:15:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:14:28 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:13:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:03:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 07:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:20:09 PM
- Nektar Therapeutics Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/08/2024 08:15:00 PM
- Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets • PR Newswire (US) • 08/01/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:02:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 08:11:19 PM
- Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 • PR Newswire (US) • 06/12/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:42 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/06/2024 04:15:16 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/05/2024 09:30:37 PM
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 10:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/28/2024 08:51:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:14:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:13:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:12:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:25:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:22:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:14:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:36:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM